Peer Review History
| Original SubmissionApril 19, 2023 |
|---|
|
PONE-D-23-11857Female sex protects against renal edema in mice with partial deletion of the endothelial barrier regulator Tie2PLOS ONE Dear Dr. van den Brom, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 29 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Keiko Hosohata, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Partly Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: Yes Reviewer #3: I Don't Know Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes Reviewer #3: No Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: 1. The little should be modified to include male and female mice. 2. There is need for critical grammatical review. 3. Wet/dry weight ratio is not the ideal test for renal and pulmonary injury, but an indicator for renal and pulmonary edeme. Medications, injections, etc can also cause edema. 4. Abstract should be revised to give a comprehensive summary of background, method, result and conclusion. 5. Conclusion shows that female mice could protect against renal edema, though the mechanism could not be explained. The preresent finding is a clear confirmation of the established findings. 6. Angiopoeitin-1 is a growth factor produced by kidney and liver, whereas angiopoeitin-2is produced and stored in Weibel-Palade bodies in endothelial cells. It binds to integrin beta-2 by interacting with platelete-derived growth factor –BB in monocytes. Hence determination of integrin and PLDGF-BB is necessary. Angiopoetin-1 signals through Tie 2, whereas angiopoetin-2 is antagonistic, hence it is a regular disruptive agent. The study was on both kidney and lung of the rats, therefore the tittle does not reflect the content. 7. Introduction should be revised to include the existing discoveries, shortcomings and the way forward. The aim of the study should be redefined. The emphasis is on the kidney and the study on both lung and kidney. Liver should have been included. 8. The methods are technical but grossly inadequate. Source, age, weight and strain of the mice are not mentioned. Period of acclimatization; cyclical diurnal changes, feeds, period of experimentation, vital parameters and generation of the mice (1st filial or 2nd filial) are not mentioned. Euthanasia using isoflurane is controversial. It is not the best drug to use. It causes behavioral changes such as induction of attention deficit, increased anxiety etc. Subheadings under Methods should be rearranged as follows: Experimental set up, Animals and Genotyping, Renal and pulmonary edema formation, Plasma analysis, Renal analysis and study approval. The use of isoflurane and decapitation is a great cruelty to Animal kingdom especially the species of mice. It is quite disheartening. Inhaled isoflurane cause pulmonary edema by atenuating histologic lung injury. I am quite wary of the use of isoflurane/decapitation. Note that isoflurane (5%) can cause death in 60 sec (too long) for humane killing. Respiratory arrest takes longer time. 9. Statistical methods should be revised. All the data presented in barcharts should be revised. Some data generated are quantitative while others are qualitative. The conclusion derived from the study based on the result is quite unfounded. The presented results are not adequately comprehensive. Therefore, I am of opinion that some results should be changed to tabular form, since males and females were used for the study. Quantitative data could be analyzed using student test unpaired. Specific relevant changes in the gene of each mice should be computed and the differences in the genes could be ranked. The Results section requires critical grammatical review. Functional parameters of kidney should have been measured. 10. Discussion should be revised. Findings should be discussed with reference to the past findings. 11. Conclusion is grossly inadequate and biased. Hence kindly revised the conclusion. Reviewer #2: Dear 1. Introduction. It is informative with compatible references 2. Methods: other than the sample size are small, it is clear and concise. Small sample size may bias the results. 3. Procedures of methods: clear and concise 4. Statistical analysis: I think with a small number of animals, it is difficult to get statistically significant. 5. The results were presented as figures, which appeared a little bit confused. The other option is to tabulate some of your findings , which be of high values to the readers as well as you impressed them. 6. Please, revised your conclusion to be more informative. Reviewer #3: Title: Female sex protects against renal edema in mice with partial deletion of the endothelial barrier regulator Tie2 Authors: N/A Review Comments to Author: The role of biological sex as a risk factor for adverse outcomes following major trauma has been widely recognized. Females may confer a protective effect against organ failure, sepsis, and mortality in patients experiencing traumatic hemorrhage. The endothelial angiopoietin/Tie2 system is well recognized for controlling the permeability of endothelial cells. In this study, in heterozygous Tie2 knock-out mice, it appears that the female sex provides protection against renal edema while not exerting the same protective effect against pulmonary edema. This study suggests that there is a sexual dimorphism that provides protection against renal edema in female mice. The study indicated that Tie2 has exhibited potential in mitigating organ edema induced by hemorrhagic shock, specifically in males. However, it is imperative to acknowledge the potential existence of sexual dimorphism in the endothelium, an aspect that has not been investigated in this particular context before. Major Comments: • The authors of the paper have done an impressive job in carrying out their research and presenting their findings. They demonstrated a good level of skill and attention to detail in executing the study and analyzing the data. Additionally, they extensively reviewed the existing literature related to their research topic, providing a comprehensive understanding of the subject matter. • However, it is important to note that the experimental design employed in the study could have been more carefully chosen. This means that there may be some limitations in how the study was designed. These flaws could potentially impact the reliability of the results obtained. • The authors investigated "whether expression of components of the endothelial angiopoietin/Tie2 system in kidneys and lungs differs between healthy female and male mice. The effect of sex on renal and pulmonary injury in heterozygous mice with genetically reduced endothelial Tie2 expression, thereby mimicking the suppressive effect of THS on expression of the endothelial Tie2 receptor." • Although the tie-2 deletion has been universal, the authors failed to explain the organ-specific effect of this particular phenotype. • The discrepancy between gene and plasma expression has not been discussed. • The abstract stated "estrogens and other endothelial barrier regulators," although only estrogen receptors have been analyzed. While estrogen has been briefly discussed with regards to its role in vasoprotective effects, the postulated selective role of TIE-2 has not been optimally elucidated in this paper. • The sample size is relatively small for assessing the claimed hypotheses. • Ln 159: Histology has not been presented anywhere in the present study, and the removal of figures has not been justified. Minor Comments: o Reference [5] are repeated many times. o A pharmacological blocker could have a superior outcome, although this has not been utilized in the study and previously utilized by your group o Ln 81, typo error o The wet/dry weight ratio approach did not show any significant difference in the present study. I wonder if there is a better mechanistic approach to show the investigated phenotype (lung vs. renal edema). o Ln 188: "Circulating levels of angiopoietin-1 (p=0.06) and angiopoietin-2 were higher in females compared to males (Fig 1A-B)" is not entirely supported by the present findings and referenced figures o Ln 199 analyzed soluble tie2, I wondered if the cellular lysate of the compared organs might show a better conclusion. o Ln 202 *, **, and *** symbols have not been included in the study. o Not all selected genes are relevant to the proposed mechanism. o Protein expression methods other than ELISA might also provide additional insight (e.g. western blotting). o The selected cohort of genes is not fully justified. The molecules included in the analysis were estrogen receptor α, estrogen receptor β, integrin α5, integrin β1, Rac1, RhoA, vascular endothelial growth factor α (VEGFα) (why not other isoforms), kidney injury molecule 1 (KIM1), and neutrophil gelatinase-associated lipocalin (NGAL). o Estrogen roles have been suggested in many reports but were not sufficiently discussed o TIE-2 has been proposed as a protective factor, although in vitro studies have been lacking. Reviewer #4: Good work. The paper is well written and discussed found that Female sex seems to protect against renal, but not pulmonary edema in heterozygous Tie2 knock-out mice. This could not be explained by sex dimorphism in the endothelial angiopoietin/Tie2 system. Reviewer #5: Leeuwen and colleagues have investigated the effect of gender on edema formation in mice with partial deletion of Tie2. Major concerns: 1- The authors have to justify why they did not use mice with full Tie2. In addition, please include the genotyping bands of three random mice in each group (in the supp material). 2- The authors relied on the w/d ratio and certain markers to conclude the edema formation. This needs further investigations such as, the albumin contents of the kidney tissues and BAL fluid as well as IHC analysis of the kidney and lung tissue to evaluate the the thickness of interalveolar septa or the tubules in the kidney tissues. 3- Tie2 receptor known to be extensively regulated on post-translational level, thus, the tissue levels of Tie2 need to be analysed (by WB or ELISA). Minor concerns: 1- please label in each figure the corresponding tissue (kidney, pulmonary...). 2- please show the IHC data (stated in the results as data not shown). 3- The authors can design a scheme to describe the proposed mechanism. Reviewer #6: Thank you for nice work and research. I have couple of recommendations: Line 72-82 Add a simplified and summarized figure about the angiopoietin/Tie2 signaling pathway Line 305-307 rewrite the two sentences regarding the pulmonary and renal gene expression to avoid duplication All Figs (1B, 1D, 2A-C, 4A, 4C, 4D, 5B, 5E, & 6F) need to be revised and fix typo of (1) ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Marwan S.M. Al-Nimer Reviewer #3: No Reviewer #4: No Reviewer #5: No Reviewer #6: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Female sex protects against renal edema, but not lung edema, in mice with partial deletion of the endothelial barrier regulator Tie2 compared to male sex PONE-D-23-11857R1 Dear Dr. van den Brom, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Keiko Hosohata, Ph.D. Academic Editor PLOS ONE Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #7: All comments have been addressed Reviewer #8: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #7: Yes Reviewer #8: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #7: Yes Reviewer #8: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #7: Yes Reviewer #8: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #7: Yes Reviewer #8: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #7: (No Response) Reviewer #8: This is interesting paper. The authors answered questions. Authors shown sex dimorphism in the endothelial angiopoietin/Tie2 system. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #7: No Reviewer #8: No ********** |
| Formally Accepted |
|
PONE-D-23-11857R1 Female sex protects against renal edema, but not lung edema, in mice with partial deletion of the endothelial barrier regulator Tie2 compared to male sex Dear Dr. van den Brom: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr Keiko Hosohata Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .